Ilyas Usman, Umar Zaryab, Pansuriya Amee M, Mahmood Abrahim, Haseeb Ul Rasool Muhammad, Bhatti Zamaraq
Internal Medicine, Icahn School of Medicine at Mount Sinai, Queens Hospital Center, Queens, USA.
Internal Medicine, New York Institute of Technology College of Osteopathic Medicine, Old Westbury, USA.
Cureus. 2023 Jan 3;15(1):e33294. doi: 10.7759/cureus.33294. eCollection 2023 Jan.
Primary appendiceal carcinomas are rare and often found incidentally when the appendix is surgically removed. Adenocarcinoma predominates the histological types of malignancies, with mucinous adenocarcinoma being the most prevalent of the various subtypes. Pseudomyxoma peritonei (PMP), a complication seen in mucinous adenocarcinoma of the appendix (MAA), is the collection of mucinous ascites in the intra-abdominal cavity and the thickening of the surrounding viscera by mucin-producing tumor cells. PMP initially presents with increased abdominal discomfort and girth and, in later stages, presents with obstructive abdomen symptoms. These symptoms are nonspecific and can be a challenge to pinpoint. Such was the case for our patient, in this case report, who initially presented with dyspepsia and later demonstrated compressive symptoms and weight loss, raising concern for malignancy. An appendiceal pathology was of concern when his right lower quadrant pain acutely worsened during an abdominal ultrasound, and imaging and biopsy confirmed MAA with PMP. The aim of this report is to shed light on the management of recurrent MAA. Our patient's recurrent MAA was managed with debulking procedures and three rounds of hyperthermic intraperitoneal chemotherapy (HIPEC) and was managed postoperatively with folinic acid, fluorouracil, and irinotecan (FOLFIRI) and bevacizumab, which in its totality helped achieve a progression-free survival of more than two years. We believe that cytoreduction and intraoperative chemotherapy prolong survival in patients with recurrent disease, as was the case with our patients. Our patient also demonstrated benefit as his disease stabilized after starting bevacizumab; however, more studies need to be performed at a larger scale to show a consistent relationship.
原发性阑尾癌很罕见,常在阑尾手术切除时偶然发现。腺癌在恶性肿瘤的组织学类型中占主导地位,黏液腺癌是各种亚型中最常见的。腹膜假黏液瘤(PMP)是阑尾黏液腺癌(MAA)中出现的一种并发症,是腹腔内黏液性腹水的积聚以及产生黏液的肿瘤细胞导致周围脏器增厚。PMP最初表现为腹部不适和腹围增加,在后期则表现为肠梗阻症状。这些症状不具有特异性,难以准确诊断。本病例报告中的患者就是如此,他最初表现为消化不良,后来出现压迫症状和体重减轻,引发了对恶性肿瘤的担忧。当他在腹部超声检查期间右下象限疼痛急性加重时,阑尾病理检查引起了关注,影像学检查和活检证实为伴有PMP的MAA。本报告的目的是阐明复发性MAA的治疗方法。我们的患者复发性MAA通过减瘤手术和三轮热灌注化疗(HIPEC)进行治疗,术后使用亚叶酸、氟尿嘧啶和伊立替康(FOLFIRI)以及贝伐单抗进行治疗,总体上帮助实现了两年多的无进展生存期。我们认为,细胞减灭术和术中化疗可延长复发性疾病患者的生存期,我们的患者就是如此。我们的患者在开始使用贝伐单抗后病情稳定,也显示出了获益;然而,需要进行更大规模的研究来证明这种一致的关系。